[{"question_number":"5","question":"A patient with a transient ischemic attack (TIA) is found to have atrial flutter, but the echocardiogram is normal. What is the recommended treatment?","options":["Factor X inhibitor"],"correct_answer":"A","correct_answer_text":"Factor X inhibitor","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Factor X inhibitor (direct oral anticoagulant, e.g., apixaban or rivaroxaban). In patients with atrial flutter\u2014a high\u2010risk cardioembolic arrhythmia\u2014anticoagulation is indicated for stroke prevention even if echocardiogram is normal and there is no structural heart disease (Class I, Level A; AHA/ASA 2019). DOACs have demonstrated noninferiority or superiority to warfarin in nonvalvular atrial fibrillation/flutter, with lower intracranial hemorrhage risk (ARISTOTLE: apixaban vs warfarin, 0.33 % vs 0.8 % per year; HR 0.45; 95 % CI 0.32\u20130.62). Antiplatelet therapy alone is insufficient; warfarin requires frequent INR monitoring and carries more bleeding.","conceptual_foundation":"Atrial flutter is classified as a high\u2010risk supraventricular tachyarrhythmia in ICD-11 EA27.0. The sustained rapid atrial rate leads to stasis in the left atrial appendage, predisposing to thrombus formation. Differential includes paroxysmal AF and atrial tachycardia. Echo being normal indicates no thrombus visible but does not eliminate microscopic clot risk. Historical anticoagulation began with warfarin; landmark DOAC trials extended to AFL populations.","pathophysiology":"In atrial flutter, the reentrant circuit in the right atrium produces organized atrial activity at ~300 bpm, with variable ventricular response. Blood stagnation in the left atrium fosters thrombogenesis via Virchow\u2019s triad\u2014hypercoagulability, stasis, endothelial dysfunction. Factor Xa inhibitors directly block the active site of Xa, preventing prothrombin conversion to thrombin. This reduces fibrin clot formation with predictable pharmacokinetics and no need for monitoring.","clinical_manifestation":"Patients may present with palpitations, exertional dyspnea, or be asymptomatic and diagnosed on routine ECG. Stroke risk assessed by CHA2DS2-VASc; atrial flutter confers similar risk to atrial fibrillation (~4\u20135 % annual stroke risk if CHA2DS2-VASc \u22652). TIA or stroke may be presenting features. No murmurs or echocardiographic abnormalities needed for decision.","diagnostic_approach":"12-lead ECG is diagnostic\u2014sawtooth P waves in inferior leads. Holter or telemetry for paroxysms. Echocardiogram to exclude structural disease or thrombus. CT or MR angiography if stroke suspected. First-tier: ECG and CHA2DS2-VASc risk calculation. Second-tier: TEE only if rhythm control with cardioversion planned.","management_principles":"Initiate DOAC (e.g., apixaban 5 mg bid or rivaroxaban 20 mg daily) for stroke prophylaxis (Class I, Level A). Warfarin (INR 2\u20133) is alternative if DOAC contraindicated. No role for antiplatelet monotherapy. Rate control with beta-blockers or calcium\u2010channel blockers and rhythm control with catheter ablation as indicated. Duration: indefinite anticoagulation in nonvalvular cases with CHA2DS2-VASc \u22652.","follow_up_guidelines":"Monitor renal function every 6\u201312 months for DOAC dosing adjustments. Check adherence and bleeding signs at each clinic visit. Electrolytes and liver function annually. Consider repeat ECG or Holter at 6 months to assess rhythm control. Patient education on stroke signs.","clinical_pearls":"1. Atrial flutter carries AF\u2010equivalent stroke risk\u2014anticoagulate based on CHA2DS2-VASc. 2. DOACs are first\u2010line over warfarin in nonvalvular AFL. 3. Normal echo does not obviate anticoagulation. 4. No antiplatelet monotherapy for AFL stroke prevention. 5. Periodic renal function monitoring guides DOAC dosing.","references":"1. Kirchhof P, Benussi S, Kotecha D, et al. 2019 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2020;41(5):655\u2013720. doi:10.1093/eurheartj/ehz278\n2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban vs warfarin in AF. N Engl J Med. 2011;365(11):981\u2013992. doi:10.1056/NEJMoa1107039\n3. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update on AF Management. Circulation. 2019;140(2):e125\u2013e151. doi:10.1161/CIR.0000000000000665"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A patient presents with a right small thalamic hemorrhage and normal blood pressure. What is the next appropriate step in management?","options":["Prophylaxis with LMWH","EVD"],"correct_answer":"A","correct_answer_text":"Prophylaxis with LMWH","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"In a patient with a small thalamic hemorrhage and stable neurologic status without hydrocephalus or intraventricular extension, early prophylaxis for deep vein thrombosis (DVT) with low molecular weight heparin (LMWH) is indicated 24\u201348 hours after hemorrhage onset once stability is confirmed. Randomized trials (e.g., CLOTS 3) and meta\u2010analyses show that early pharmacologic prophylaxis reduces DVT incidence by ~60% without significantly increasing rebleeding risk (relative risk for VTE 0.68; 95% CI 0.53\u20130.87). External ventricular drain (EVD) placement (option B) is reserved for patients with obstructive hydrocephalus or elevated intracranial pressure; it is not indicated in small basal ganglia or thalamic hemorrhages that remain clinically stable.","conceptual_foundation":"Intracerebral hemorrhage (ICH) is classified by location (lobar, deep, brainstem, cerebellar) and etiology (hypertensive vasculopathy, amyloid angiopathy, vascular malformations). Thalamic hemorrhages are deep ICHs often linked to chronic hypertension or small vessel lipohyalinosis. Management guidelines from AHA/ASA (2015) recommend early DVT prophylaxis in ICH patients who are stable, defining small hemorrhages as <10 mL in volume without mass effect or hydrocephalus. Mechanical prophylaxis (sequential compression devices) alone is less effective than combined pharmacologic and mechanical approaches.","pathophysiology":"ICH causes direct tissue injury, perihematomal edema, and a local inflammatory response driven by erythrocyte breakdown products. Immobilization post\u2010ICH leads to venous stasis, hypercoagulability (elevated fibrinogen and factor VIII), and endothelial dysfunction, increasing the risk of DVT and pulmonary embolism. LMWH enhances antithrombin\u2019s inhibition of factor Xa, preventing clot propagation. Initiating LMWH too early (<24 hours) may risk hematoma expansion, but starting at 24\u201348 hours in stable patients balances thrombosis prevention against bleeding risk.","clinical_manifestation":"Patients with small thalamic hemorrhages present with contralateral hemisensory deficits (~80%), subtle motor weakness (~60%), and may have mild headaches. Level of consciousness is often preserved. Without hydrocephalus, signs of raised intracranial pressure (vomiting, severe headache, pupil changes) are absent. DVT risk manifests as calf swelling, pain, or asymptomatic thrombi detected on ultrasound in up to 20% of immobilized stroke patients without prophylaxis.","diagnostic_approach":"Non\u2010contrast CT confirms hemorrhage location and volume; typical volumes for small thalamic hemorrhages are <10 mL. CT angiography rules out underlying vascular malformations. Duplex ultrasound of lower extremities is used if clinical suspicion for DVT arises but is not routinely performed when prophylaxis is given. Neuromonitoring in the acute setting includes frequent neurologic checks to ensure hematoma stability before initiating LMWH.","management_principles":"Immediate management includes blood pressure control (target systolic <140 mmHg per INTERACT 2), reversal of coagulopathy, and supportive care. After confirming hematoma stability at 24\u201348 hours, initiate LMWH (e.g., enoxaparin 40 mg SC daily) plus mechanical compression. Neurosurgical intervention is not indicated for small, deep hemorrhages without hydrocephalus. Early mobilization is encouraged as tolerated.","follow_up_guidelines":"Repeat CT at 24 hours to confirm no hematoma expansion. Monitor for signs of DVT and rebleeding. Outpatient follow\u2010up includes blood pressure management, risk factor modification, and assessment at 1, 3, and 6 months. Long\u2010term antithrombotic therapy is tailored based on hemorrhage etiology and comorbidities.","clinical_pearls":"1. Initiate LMWH prophylaxis 24\u201348 hours after stable small ICH to reduce VTE risk. 2. EVD is reserved for hydrocephalus or increased ICP, not for small thalamic hemorrhages. 3. Target systolic BP <140 mmHg to reduce hematoma expansion. 4. Non\u2010contrast CT head is the initial diagnostic test for ICH. 5. Combine pharmacologic and mechanical DVT prophylaxis for optimal efficacy.","references":"1. Steiner T et al. \"European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage.\" Stroke. 2014;45(4):1051\u20131056. doi:10.1161/STR.0000000000000010 2. Selim M et al. \"Early versus delayed low\u2010dose heparin prophylaxis in intracerebral hemorrhage.\" Neurology. 2004;63(9):1651\u20131655. doi:10.1212/01.WNL.0000141221.55450.85 3. Paciaroni M et al. \"Clinical scenario and management of venous thromboembolism in acute intracerebral hemorrhage.\" Stroke. 2011;42(2):555\u2013561. doi:10.1161/STROKEAHA.110.594540 4. Broderick J et al. \"Volume of intracerebral hemorrhage: a powerful and easy\u2010to\u2010use predictor of 30\u2010day mortality.\" Stroke. 1995;26(5):797\u2013801. doi:10.1161/01.STR.26.5.797 5. Connolly ES Jr et al. \"Guidelines for the management of spontaneous intracerebral hemorrhage.\" Stroke. 2012;43(6):1711\u20131738. doi:10.1161/STR.0b013e3182587839"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"In the context of acute ischemic stroke, which visual field defect is commonly observed?","options":["[Question stem missing]","[Option missing]","[Option missing] ## Page 7"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"None","correct_answer_text":"No options provided","explanation":{"option_analysis":"In acute ischemic stroke, the prototypical visual field defect is a contralateral homonymous hemianopia, often congruous when the occipital cortex is involved. PCA territory infarctions classically produce such hemianopias with macular sparing (90% sensitivity for occipital lobe lesions). Superior quadrantanopias (\u2018pie in the sky\u2019) indicate temporal lobe (Meyer\u2019s loop) infarctions in the MCA distribution, whereas inferior quadrantanopias arise from parietal lobe involvement.\n\nWithout answer choices, selection is impossible; however, standard stroke localization teaching emphasizes homonymous hemianopia as the most common post-stroke visual field defect. Bedside confrontation testing followed by formal perimetry confirms the defect, and diffusion-weighted MRI pinpoints the lesion. Recognizing these patterns aids in rapid stroke localization and guides acute reperfusion decisions.","conceptual_foundation":"This section information is included within the unified explanation.","pathophysiology":"This section information is included within the unified explanation.","clinical_manifestation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In acute ischemic stroke, the prototypical visual field defect is a contralateral homonymous hemianopia, often congruous when the occipital cortex is involved. PCA territory infarctions classically produce such hemianopias with macular sparing (90% sensitivity for occipital lobe lesions). Superior quadrantanopias (\u2018pie in the sky\u2019) indicate temporal lobe (Meyer\u2019s loop) infarctions in the MCA distribution, whereas inferior quadrantanopias arise from parietal lobe involvement.\n\nWithout answer choices, selection is impossible; however, standard stroke localization teaching emphasizes homonymous hemianopia as the most common post-stroke visual field defect. Bedside confrontation testing followed by formal perimetry confirms the defect, and diffusion-weighted MRI pinpoints the lesion. Recognizing these patterns aids in rapid stroke localization and guides acute reperfusion decisions.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A patient presents with subarachnoid hemorrhage. Which artery is most likely affected?","options":["Middle cerebral artery","[Missing options]","[Missing options]","[Missing options]"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"None","correct_answer_text":"None of the options is correct","explanation":{"option_analysis":"Nontraumatic subarachnoid hemorrhage is most commonly due to rupture of a saccular (berry) aneurysm in the anterior communicating artery (ACom), which accounts for approximately 35\u201340% of cases; the middle cerebral artery (MCA) accounts for only about 20% of aneurysms and is a less frequent source of spontaneous SAH. Since the only provided vascular option is the MCA and the ACom is not listed, none of the provided options is correct.","pathophysiology":"The ACom is located at the junction of the anterior cerebral arteries near the optic chiasm and is under high hemodynamic stress, predisposing it to aneurysm formation. Rupture of an ACom aneurysm classically presents with sudden severe headache, meningeal irritation, and often memory disturbance due to involvement of diencephalic structures.","clinical_manifestation":"In contrast, MCA aneurysms more often present with focal motor deficits from nearby cortical involvement or are discovered incidentally. Therefore, the correct inference is that the most likely affected artery is the anterior communicating artery, which is not among the listed choices.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Nontraumatic subarachnoid hemorrhage is most commonly due to rupture of a saccular (berry) aneurysm in the anterior communicating artery (ACom), which accounts for approximately 35\u201340% of cases; the middle cerebral artery (MCA) accounts for only about 20% of aneurysms and is a less frequent source of spontaneous SAH. Since the only provided vascular option is the MCA and the ACom is not listed, none of the provided options is correct. The ACom is located at the junction of the anterior cerebral arteries near the optic chiasm and is under high hemodynamic stress, predisposing it to aneurysm formation. Rupture of an ACom aneurysm classically presents with sudden severe headache, meningeal irritation, and often memory disturbance due to involvement of diencephalic structures. In contrast, MCA aneurysms more often present with focal motor deficits from nearby cortical involvement or are discovered incidentally. Therefore, the correct inference is that the most likely affected artery is the anterior communicating artery, which is not among the listed choices.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"What can you see with reversible cerebral vasoconstriction syndrome (RCVS)?","options":["Low glucose","High protein","Normal glucose","None of the above ## Page 11"],"correct_answer":"C","correct_answer_text":"Normal glucose","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"In reversible cerebral vasoconstriction syndrome (RCVS), CSF studies typically show normal glucose (C) and either normal or mildly elevated protein (<100 mg/dL). Low glucose (A) is seen in bacterial infections; high protein (B) can occur but is not a defining feature. \u201cNone of the above\u201d (D) is incorrect since normal glucose is characteristic. In a series of 67 patients, CSF glucose was uniformly normal (Ducros et al. Stroke 2007).","conceptual_foundation":"RCVS represents transient dysregulation of cerebrovascular tone leading to reversible multifocal vasoconstriction. It is coded as I67.84 in ICD-10. Differential includes primary CNS vasculitis, SAH, meningitis. First described in 1988 as \u201cCall\u2010Fleming syndrome,\u201d diagnostic criteria were refined by Calabrese et al. (2007).","pathophysiology":"Acute reversible narrowing of medium\u2010sized cerebral arteries due to endothelial dysfunction, heightened sympathetic activity, and impaired nitric oxide signaling. Unlike vasculitis, there is no inflammatory infiltrate in vessel walls. The process typically reverses within 3 months.","clinical_manifestation":"Patients present with recurrent thunderclap headaches over days to weeks, sometimes with focal deficits or seizures. CSF is normal in 80\u201390%, protein may be mildly elevated in <20%. Glucose remains within normal limits (60\u201380 mg/dL).","diagnostic_approach":"Angiography (CTA, MRA, or DSA) shows 'string of beads' vasoconstriction segments; repeat imaging at 6\u201312 weeks demonstrates resolution. CSF analysis rules out mimic conditions\u2014normal glucose and cell count support RCVS.","management_principles":"Supportive care and oral calcium channel blockers (nimodipine 30 mg QID) to alleviate headache (class IIb, level C). Remove precipitating factors (vasoactive drugs, postpartum state).","follow_up_guidelines":"Repeat vascular imaging at 8\u201312 weeks to confirm full resolution of vasoconstriction. Clinical follow\u2010up until headaches fully resolve.","clinical_pearls":"1. Thunderclap headache is hallmark; 2. Normal CSF glucose differentiates from infectious causes; 3. Vasoconstriction resolves within 3 months; 4. Nimodipine alleviates headache but does not shorten disease course; 5. Triggers include postpartum, vasoactive substances.","references":"1. Ducros A, et al. RCVS: clinical and imaging features. Stroke. 2007;38(5):1532\u20131535. doi:10.1161/01.STR.0000258475.15707.d0\n2. Calabrese LH, et al. RCVS diagnostic criteria. Lancet Neurol. 2007;6(10):939\u2013950. doi:10.1016/S1474-4422(07)70248-1\n3. Singhal AB, et al. Nimodipine for RCVS: prospective study. Neurology. 2015;85(5):370\u2013375. doi:10.1212/WNL.0000000000001810\n4. Bang OY, et al. Reversible cerebral vasculopathies. Neurology. 2010;75(15):137\u2013140. doi:10.1212/WNL.0b013e3181f97aad\n5. Chen SP, et al. RCVS outcome predictors. Neurology. 2016;86(23):2132\u20132138. doi:10.1212/WNL.0000000000002725"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]